Background: Clinical and preclinical studies suggest that selective activators of the muscarinic M4 receptor have exciting potential as a novel approach for treatment of schizophrenia. M4 reduces striatal dopamine (DA) though release of endocannabinoids (eCB), providing a mechanism for local effects on DA signaling in the striatum. M4 signals through Gαi/o and does not couple to Gαq/11 or induce calcium (Ca++) mobilization. This raises the possibility that M4-induced eCB release and inhibition of DA release may require co-activation of another receptor that activates Gαq/11. If so, this receptor could provide a novel target that may be more proximal to inhibition of DA release. Interestingly, the group 1 metabotropic glutamate (mGlu) receptors (mGlu1 and Glu5), couple to Gαq/11 and activate eCB signaling in multiple brain regions. Methods: We tested the hypothesis that M4-induced reductions in DA release and subsequent antipsychotic-effect requires co-activation of group 1 mGlu receptors. The effect of M4 activation on electrically-evoked DA release in striatal slices was assessed using fast-scan cyclic voltammetry (FSCV) in the absence or presence of selective negative allosteric modulators (NAMs) of group 1 mGlu receptor subtypes. To evaluate the potential role of mGlu1, we determined the effects of a selective mGlu1 positive allosteric modulators (PAMs) on striatal DA release and antipsychotic-like activity in rodent models that are dependent on increased DA transmission. Since reductions in DA signaling, including D1 signaling have been implicated in reduced motivation, we also determined the effects of an mGlu1 PAM, M4 PAM, and the typical antipsychotic haloperidol on motivational responding in a progressive ratio (PR) schedule. Results: We now present exciting new data in which we found that activation of mGlu1 through application of exogenous agonists or selective stimulation of thalamostriatal afferents induces a reduction of striatal DA release and that selective mGlu1 PAMs have robust antipsychotic-like effects in rodent models. Interestingly, our studies also suggest that mGlu1 activation is required for M4 PAM-induced inhibition of DA release and antipsychotic-like effects. However, in contrast to available antipsychotic agents, the present results and previous studies suggest that mGlu1 and M4 PAMs reduce DA signaling through local release of an eCB from striatal SPNs and activation of CB2 receptors on neighboring DA terminals to reduce DA release. While these studies suggest that the effects of M4 PAMs on DA release require activation of mGlu1, we have also found that these targets have important differences. Most notably, M4 PAMs also directly inhibits D1 signaling in D1-SPN terminals in the substatnia nigra pars reticulata (SNr). Unlike M4, mGlu1 does not directly inhibit DA D1 receptor signaling and does not induce behavioral changes that could be associated with negative symptoms. Discussion: Our findings are especially interesting in light of recent findings that multiple loss of function single nucleotide polymorphisms (SNPs) in the human gene encoding mGlu1 (GRM1) are associated with schizophrenia, and points to GRM1/mGlu1 as a gene within the "druggable genome" that could be targeted for treatment of schizophrenia. Recent clinical imaging studies suggesting that symptoms in schizophrenia patients are associated with selective increases in striatal DA signaling and while extrastriatal regions display hypo-dopaminergic function; thus, mGlu1 and M4 PAMs may provide a mechanism for selective inhibition of DA release in striatal regions that are important for antipsychotic efficacy, without further disruptions in extrastriatal DA signaling.
T228. VARIABILITY AND UNDERUTILISATION OF CLOZAPINE IN SPAIN
Francisco Javier Sanz-Fuentenebro* Background: The analysis of the information available in many countries on the use of clozapine, systematically indicates low prescription, underdosing and delay in the start of treatment. But as striking as this underutilization is the great variability between territories studied, which are related to multiple factors, and have led to various initiatives to improve its use. We do not have studies that evaluate these aspects in the Spanish population, so we have considered a first approximation through samples from four territories. Methods: The authors analyzed the prescription data of clozapine in Castilla y León, the Basque Country, Catalonia and a Southern Madrid Area. Results: The patients diagnosed with schizophrenia who receive treatment in the territories studied oscillate around 0.3%; the treatments with clozapine / 10000 inhabitants between 33.0 and 57.0; and patients diagnosed as schizophrenia receiving clozapine account for between 13.7% and 17.9% of those treated. The coefficient of variation between centers and prescribers is frequently higher than 50%. Discussion: The global clozapine prescription data in the territories studied are in the range of countries in our environment. Background: Altered levels of free Thyroxin (fT4) and Thyroid Stimulating Hormone (TSH) have been associated with severe mental disorders and the use of antipsychotic drugs. Still, there is a lack of studies systematically investigating commonly prescribed antipsychotic drugs and thyroid function. We investigated the association of antipsychotic drugs and thyroid hormones levels in patients with severe mental disorders and compared thyroid function tests between patients and healthy controls under real-life conditions. Methods: We included 1345 patients with schizophrenia or bipolar disorders and 989 healthy controls from the on-going Thematically Organized Psychosis (TOP) study, recruiting participants between 18-65 years of age in and around Oslo, Norway. All patients underwent a thorough clinical investigation including diagnostic evaluation, somatic screening and assessment of medication data. Serum drug concentrations were measured. Plasma levels of fT4 and TSH were measured in patients and healthy controls, and thyroid status was determined based on the combined hormone levels. Participants with known thyroid function disorders (N=28) were excluded. Mann-Whitney U tests and chi-square tests were performed for comparison between groups. For evaluation of influence from antipsychotics, multiple linear regression analyses were performed, adjusting for patient/control status, age, sex and use of other psychopharmacological agents. Associations with the use of olanzapine, quetiapine, aripiprazole or risperidone in monotherapy were analyzed in a subsample of patients (N=480), adjusting for age, sex and diagnosis. Spearman correlation analyses were performed for hormone levels and drug serum concentrations. Results: We found significant lower levels of fT4 (median 13.70 vs 14.00, p<0.001) and higher levels of TSH (median 1.92 vs 1.57, p<0.001) in patients compared to healthy controls. A significant difference between patients and controls in occurrence of hyper-and hypothyreosis was observed (p<0.001), with more than three times as many patients compared to controls with hypothyroid status (11.1% vs 3.4%), and a doubling of hyperthyroid status (2.3% vs. 1.2%). Use of antipsychotics was significantly
